Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 2581 results for methods

  1. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA765)

    Evidence-based recommendations on venetoclax (Venclyxto) with azacitidine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA765

  2. Midostaurin for treating advanced systemic mastocytosis (TA728)

    Evidence-based recommendations on midostaurin (Rydapt) for treating advanced systemic mastocytosis in adults.

    Technology appraisal guidance
    Published
    22 September 2021
    View recommendations

    Sections for TA728

  3. Naltrexone–bupropion for managing overweight and obesity (TA494)

    Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults.

    Technology appraisal guidance
    Published
    12 December 2017
    View recommendations

    Sections for TA494

  4. Cabozantinib for untreated advanced renal cell carcinoma (TA542)

    Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    3 October 2018
    View recommendations

    Sections for TA542

  5. Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (TA787)

    Evidence-based recommendations on venetoclax (Venclyxto) with low dose cytarabine for untreated acute myeloid leukaemia in adults when intensive chemotherapy is unsuitable.

    Technology appraisal guidance
    Published
    27 April 2022
    View recommendations

    Sections for TA787

  6. Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)

    Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA525

  7. Arsenic trioxide for treating acute promyelocytic leukaemia (TA526)

    Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    13 June 2018
    View recommendations

    Sections for TA526

  8. Colon cancer (adjuvant) - irinotecan [ID379]

    In development Reference number: GID-TAG380 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]

    In development Reference number: GID-TA10577 Expected publication date:  21 April 2021

    Technology appraisal guidance
    In development

  10. Hypercholesterolaemia (primary), dyslipidaemia (mixed) - anacetrapib [ID1165]

    Discontinued Reference number: GID-TA11175

    Technology appraisal guidance
    Discontinued

  11. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Pembrolizumab with lenvatinib and chemotherapy for untreated metastatic squamous cell oesophageal cancer [TSID12096]

    In development Reference number: GID-TA11627 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    Discontinued Reference number: GID-HST10033

    Highly specialised technologies guidance
    Discontinued

  14. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920

    In development Reference number: GID-TA11482 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued Reference number: GID-TA10863

    Technology appraisal guidance
    Discontinued